Sixfold Bioscience
Preclinical-stage biotechnology company developing programmable RNA delivery systems. The company combines generative machine learning, automated chemistry, and high-throughput in vivo screening to design chemically encoded RNA delivery tags and conjugates for oligonucleotide therapeutics (siRNA, ASO). Based in White City, London, the organisation maintains laboratory synthesis and analytical capabilities and collaborates with academic and industrial partners.
Industries
Nr. of Employees
small (1-50)
Patents
Compositions containing nucleic acid nanoparticles with modular functionality
US-12472267-B2
View DetailsCompositions containing nucleic acid nanoparticles with modular functionality
US-11357865-B2
View Details
Compositions containing nucleic acid nanoparticles with modular functionality
US-12472267-B2
View DetailsCompositions containing nucleic acid nanoparticles with modular functionality
US-11357865-B2
View DetailsProducts
Programmable RNA delivery platform (conjugation-based)
A platform that encodes delivery information into RNA via chemical modifications and conjugates to bias biodistribution and cellular uptake for short oligonucleotides.
Mergo
A programmable RNA tag designed to encode RNA modifications and iterable design elements to influence the delivery destination of RNA therapeutics.
Programmable RNA delivery platform (conjugation-based)
A platform that encodes delivery information into RNA via chemical modifications and conjugates to bias biodistribution and cellular uptake for short oligonucleotides.
Mergo
A programmable RNA tag designed to encode RNA modifications and iterable design elements to influence the delivery destination of RNA therapeutics.
Services
Collaborative research and development partnerships to design, synthesise and screen chemically encoded RNA delivery constructs and conjugates for target cell types.
Collaborative research and development partnerships to design, synthesise and screen chemically encoded RNA delivery constructs and conjugates for target cell types.
Expertise Areas
- RNA delivery technology development
- Generative machine learning for molecular design
- High-throughput in vivo screening and multiplexed assays
- Oligonucleotide conjugation chemistry
Key Technologies
- Generative machine learning (variational autoencoders)
- Gaussian process decoders
- Bayesian optimization
- Design of Experiments (DoE)
News & Updates
Co-CEO presented on computational and chemical strategies for oligonucleotide delivery.
Awarded UKRI funding for a four-year project to advance generative ML and Bayesian optimisation for RNA delivery.
Presentation on recurrent VAE with Gaussian Process decoders for de novo molecular generation.
Added laboratory space and equipment (RNA synthesis and analytical tools) to increase throughput for delivery construct synthesis and in vivo dataset generation.
Coverage in Nature Biopharma discussing the company's approach to targeted RNA delivery.
Peer-reviewed publication discussing natural RNA transport mechanisms relevant to delivery strategies.
Co-CEO presented on computational and chemical strategies for oligonucleotide delivery.
Awarded UKRI funding for a four-year project to advance generative ML and Bayesian optimisation for RNA delivery.
Presentation on recurrent VAE with Gaussian Process decoders for de novo molecular generation.
Added laboratory space and equipment (RNA synthesis and analytical tools) to increase throughput for delivery construct synthesis and in vivo dataset generation.
Coverage in Nature Biopharma discussing the company's approach to targeted RNA delivery.
Peer-reviewed publication discussing natural RNA transport mechanisms relevant to delivery strategies.